image credit- istock.com
OliX Pharmaceuticals, Inc., a leading developer of RNAi therapeutics in South Korea, announced an expansion of its ocular disease pipeline. Specifically, the company announced that OLX304A has been added to develop an RNAi therapeutic with a novel target (undisclosed) for treatment of Retinitis Pigmentosa (RP) in a presentation at the Investor Relations Meeting in Seoul on May 10th.
OLX304A is a program to develop a treatment that targets a single gene for RP patients regardless of their disease-causing gene mutation. This strategy is different from the conventional treatment development strategies for RP which target individual disease-causing genes.
An IND application of OLX304A program is planned to be submitted to the US FDA to initiate a Phase 1 within the first half of next year.
